← All trials
NCT04895579
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 12, 2021
- Primary completion
- Jun 30, 2031
- Completion date
- Jun 30, 2031
- First posted
- May 20, 2021
- Last posted
- May 20, 2021
- Enrollment
- 18
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of KentuckyLead sponsor
- BayerCollaborator
- University of KentuckyOverall official - principal investigator
- University of KentuckySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.